AbbVie defends privacy on data; Vivus asks advice of EU for Qsymia; Pay whatever drugs cost, U.K. survey says;

@FiercePharma: Sanofi CEO: Thanks to Genzyme, investors take us seriously. ICYMI yesterday | Follow @FiercePharma

@EricPFierce: Ranbaxy's hair in tablet issue will shave its Q3 earnings, analyst tells ETReport | Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Purdue hands California list of risky OxyContin prescribers. Article | Follow @CarlyHFierce

> An AbbVie ($ABBV) executive defended the company position that its information on adverse reactions and some other data should be considered confidential and only given to those who promise not to share it. Video

> Vivus ($VVUS) said today that it will work with European regulators in hopes of its getting weight-loss drug Qsymia approved there after regulators there have twice turned it down. Release

> GlaxoSmithKline ($GSK) has gotten a nearly $200 million contract with the U.S. to provide its inhalation anthrax treatment, raxibacumab, which was approved by the FDA last year. Story

> Baxter International ($BAX) announced today it has initiated a voluntary recall of two lots of its Dual Luer Lock Caps because of the presence of loose particulate matter found in the packaging. Release

Medical Device News

@FierceMedDev: Covidien plots job cuts, plant closures to save $300M. ICYMI yesterday | Follow @FierceMedDev

@DamianFierce: Ocular Therapeutix inches toward FDA approval with a panel thumbs-up. Story | Follow @DamianFierce

@MarkHFierce: A jury awarded Retractable Technologies $100M-plus in a patent lawsuit verdict against Becton Dickinson. Release | Follow @MarkHFierce

@MichaelGFierce: The artificial pancreas combines an  with a continuous glucose monitor. Who will get one to market first? Special report from FierceDrugDelivery | Follow @MichaelGFierce

> Sapheon begins PMA process for varicose vein treatment. Story

> J&J vaginal mesh class-action suit grows in Australia. Item

> Baxter recalls caps over deadly embolism risk. Article

Biotech News

@FierceBiotech: ICYMI yesterday - Google's biotech plan: Partner with legendary CEO, tackle aging, think outside the cancer box. Article | Follow @FierceBiotech

@JohnCFierce: Bind (Langer) raised $70.5M in its IPO. Priced in the range. Press release | Follow @JohnCFierce

@EmilyMFierce: A molecular decoy could treat the most common type of human dwarfism. More via Science | Follow @EmilyMFierce

> Merck's Perlmutter shares plans for R&D reboot, likes and dislikes. Story

> San Diego biotech insider accused of shooting RNAi expert and brother-in-law. Report

> EU body endorses 11 new drugs from Glaxo, Roche, J&J and others. More

> Muscular dystrophy drug from GlaxoSmithKline, Prosensa fails PhIII. Article

And Finally... A survey sponsored by Novartis ($NVS), Roche ($RHHBY) and Sanofi ($SNY) in the U.K. says that half of the respondents believe the National Health Service should "pay for all treatments regardless of how much they cost, going beyond international standard practice." Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.